Price$5.79+0.29 (+5.18%)
01:30 PM07:45 PM
News · 26 weeks66+45%
2026-01-182026-07-12
Mix4090d
- Insider14(35%)
- Other12(30%)
- SEC Filings11(28%)
- Earnings2(5%)
- Offering1(3%)
Latest news
25 items- INSIDERChief Financial Officer Sauvage Philippe exercised 40,000 shares at a strike of $2.17, increasing direct ownership by 283% to 54,131 units (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- SECNuvation Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes OfferingNEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise. On July 1, 2
- SECNuvation Bio Inc. filed SEC Form 8-K: Other Events, Entry into a Material Definitive Agreement8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United KingdomFOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approvalNEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell
- SECSEC Form 424B5 filed by Nuvation Bio Inc.424B5 - Nuvation Bio Inc. (0001811063) (Filer)
- SECSEC Form 305B2 filed by Nuvation Bio Inc.305B2 - Nuvation Bio Inc. (0001811063) (Filer)
- SECSEC Form FWP filed by Nuvation Bio Inc.FWP - Nuvation Bio Inc. (0001811063) (Subject)
- PRNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesNEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million. The sale of the Notes to the underwriters is expected to close on June 30, 2026, subject to customary closing conditions. Nuvation Bio also granted the underwriters of the Notes a right to purchase, exercisable within 30 days
- SECSEC Form 424B5 filed by Nuvation Bio Inc.424B5 - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Announces Proposed Convertible Senior Notes OfferingNEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if
- INSIDERCHIEF PEOPLE OFFICER Markel Stacy exercised 125,000 shares at a strike of $1.83 and sold $753,188 worth of shares (125,000 units at $6.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERCHIEF REGULATORY OFFICER Wentworth Kerry exercised 63,000 shares at a strike of $2.93 and sold $379,191 worth of shares (63,000 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERChief Financial Officer Sauvage Philippe exercised 47,668 shares at a strike of $2.17 and sold $286,370 worth of shares (47,668 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- SECSEC Form 144 filed by Nuvation Bio Inc.144 - Nuvation Bio Inc. (0001811063) (Subject)
- SECSEC Form 144 filed by Nuvation Bio Inc.144 - Nuvation Bio Inc. (0001811063) (Subject)
- INSIDERDirector Mashal Robert bought $118,250 worth of shares (25,000 units at $4.73) (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- SECSEC Form 8-K filed by Nuvation Bio Inc.8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio to Present at the Jefferies Global Healthcare ConferenceNEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m. ET in New York, NY. A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bi
- PRNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatmentCognitive function scores improved or remained stable throughout the course of treatment with IBTROZIIBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breathNEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung can
- INSIDERSEC Form 4 filed by Director Vernon W Anthony4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Mashal Robert4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Falberg Kathryn E4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Blickenstaff Kim D4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Bazemore Robert B4 - Nuvation Bio Inc. (0001811063) (Issuer)
NUVB FAQ
7 questionsWhat does Nuvation Bio Inc. do?
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells...Where does NUVB stock trade?
Nuvation Bio Inc. (NUVB) is listed on NYSE.What sector and industry is NUVB in?
Nuvation Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvation Bio Inc. go public?
Nuvation Bio Inc. (NUVB) completed its IPO in 2020.What are analysts saying about NUVB?
Nuvation Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2025-11-24.What companies are similar to NUVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NUVB side-by-side with any of them on Quantisnow.How can I track NUVB on Quantisnow?
Quantisnow aggregates Nuvation Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUVB to receive live email and push alerts on every new disclosure.